<Suppliers Price>

Anecortave Acetate

Names

[ CAS No. ]:
7753-60-8

[ Name ]:
Anecortave Acetate

[Synonym ]:
2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
21-Acetoxy-17-hydroxy-pregna-4,9(11)-dien-3,20-dion
Retaane
21-acetoxy-17-hydroxy-pregna-4,9(11)-diene-3,20-dione
AL-3789
2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate
Anecortave
Anecortave acetate
Retaane suspension

Biological Activity

[Description]:

Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2].

[Related Catalog]:

Signaling Pathways >> Metabolic Enzyme/Protease >> PAI-1
Research Areas >> Cardiovascular Disease

[Target]

PAI-1[2]


[In Vivo]

Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels[2]. Animal Model: Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)[2] Dosage: 5 μl of a 10% suspension of Anecortave acetate Administration: Injected into eyes Result: significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels. Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.

Chemical & Physical Properties

[ Density]:
1.23g/cm3

[ Boiling Point ]:
551.8ºC at 760 mmHg

[ Molecular Formula ]:
C23H30O5

[ Molecular Weight ]:
386.48100

[ Flash Point ]:
188.4ºC

[ Exact Mass ]:
386.20900

[ PSA ]:
80.67000

[ LogP ]:
3.30170

[ Index of Refraction ]:
1.572

Synthetic Route

Precursor & DownStream


Related Compounds